<DOC>
	<DOCNO>NCT00871546</DOCNO>
	<brief_summary>Participants randomize SCH 727965 comparator drug ( bortezomib mantle cell lymphoma [ MCL ] alemtuzumab B cell chronic lymphocytic leukemia [ B CLL ] ) . Part 1 study determine activity SCH 727965 treatment participant MCL participant B-CLL . Part 2 study determine activity SCH 727965 treatment participant experience disease progression standard treatment comparator drug Part 1 .</brief_summary>
	<brief_title>SCH 727965 Patients With Mantle Cell Lymphoma B-Cell Chronic Lymphocytic Leukemia ( Study P04715 )</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Alemtuzumab</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>Age &gt; =18 year , either sex , race . Eastern Cooperative Oncology group performance status 0 1 . Adequate hematologic , renal , hepatic organ function laboratory parameter . For subject MCL : Diagnosis MCL accord World Health Organization ( WHO ) criterion . Received least one prior chemotherapeutic regimen , two regimen include stem cell transplantation.. Measurable assessable disease Revised Response Criteria Malignant Lymphoma . For subject BCLL Documented BCLL accord National Cancer Institute Working Group ( NCIWG ) criterion . Received least one prior alkylating agentbased regimen one fludarabine pentostatincontaining regimen , must receive two prior regimen . Measurable assessable disease NCIWG criterion . Known central nervous system involvement MCL BCLL . Previous treatment SCH 727965 cyclindependent kinase inhibitor . For MCL , previous treatment bortezomib . For BCLL , previous treatment alemtuzumab . Known HIV infection . Known active hepatitis B C .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>